Terrence Hallahan: Enhancing Preeclampsia Prevention Through Aspirin Dose Adjustment
Terrence Hallahan, Director, Prenatal Screening Laboratory at Northwell Health Labs, shared a post on LinkedIn about a paper by Maura E. Jones Pullins et al. published in AJOG MFM:
“My recent post on preeclampsia prevention sparked a great conversation about aspirin dosage! Let’s dive into why 162mg of aspirin is increasingly preferred over 81mg for high-risk women preventing pre-term preeclampsia:
Enhanced Efficacy in High-Risk Women:
Seminal research (like Roberg’s meta-analysis) established that aspirin is effective against preterm (<37 weeks) preeclampsia (not term), requires initiation prior to 16 weeks gestation, and shows a clear dose-effect, with >100mg offering greater risk reduction.
The landmark ASPRE trial (150mg aspirin vs. placebo) demonstrated a remarkable 62% reduction in pre-term preeclampsia in the aspirin group.
Recent meta-analyses consistently note greater pre-eclampsia risk reduction with the 150- to 162-mg dose compared to 75- to 81-mg.
Importantly, in obese patients (20-40% of the population), 162mg has been demonstrated to be more effective.
Pharmacological Considerations:
The goal of low-dose aspirin (LDA) is to inhibit platelet cyclooxygenase-1 (COX-1) to reduce thromboxane A2. However, platelet aggregation assays show that up to 30% of women exhibit aspirin resistance at 81mg. This resistance is largely overcome at the 162mg dose, ensuring more consistent thromboxane A2 inhibition, crucial for preventing vasoconstriction.
Safety Profile:
Crucially, studies confirm that increasing the dose from 81mg to 162mg does not significantly increase the risk of maternal or fetal bleeding complications or other adverse events. Both doses are still considered ‘low-dose’ aspirin, making the 162mg dose favorable given its improved efficacy.
Professional Guidelines:
Although ACOG‘s primary recommendation is 81 mg, international organizations such as NICE (UK), FIGO and ISUOG all recommend higher doses, typically in the range of 100 mg to 150 mg daily. SOGC (Canada) allows for 81-162mg.
In essence, the evidence now strongly supports 162mg for superior, safe, and effective pre-term preeclampsia prevention.
For more detail see this expert review.
What are your thoughts or experiences with aspirin dosing in your practice?”
Title: Aspirin dosage for preeclampsia prophylaxis: an argument for 162-mg dosing
Authors: Maura E. Jones Pullins, Kim A. Boggess
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 28, 2026, 16:59Unlocking the Potential of Menstrual Blood in Health Testing – Global Women’s Health Innovation Conclave
-
Jan 28, 2026, 16:57New Insights on Oocyte Yield in Endometriosis and PCOM – RBMO
-
Jan 28, 2026, 16:51Transform Your Expertise with ESHRE eCampus Learning – ESHRE
-
Jan 28, 2026, 16:46Accelerate Your Growth at the AP3G National Meeting – ASRM
-
Jan 28, 2026, 16:43Debojit Saha: Unraveling Chromosomal Errors in Aging Human Eggs
-
Jan 28, 2026, 16:38Silvia Vannuccini: RBMO Highlights Key Insights on Adenomyosis Awareness
-
Jan 28, 2026, 16:32Maximilian Attwood: Challenging Medical Misogyny in Endometriosis Research
-
Jan 28, 2026, 16:29Ioakeim Sapantzoglou: New Perspectives on Fetal Growth Restriction and Genetic Testing
-
Jan 28, 2026, 16:26Enhancing Pre-Eclampsia Prediction with Doppler Indices – ISUOG